Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of gemcitabine + carboplatin + sorafenib in advanced solid tumors
NL-OMON31053Phase 1Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2007
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine, carboplatin and sorafenib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), bladder cancer and 2 more, sponsored by Netherlands Cancer Institute. Primary endpoints: Safety and tolerability and Maximum tolerated dose and dose-limiting toxicity. Planned start Sep 2007; status: not yet recruiting.
02
Drugs
gemcitabinecarboplatinsorafenib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)bladder cancerpancreatic cancer (PC)ovarian cancer
Beyond the preview
Go deeper on NL-OMON31053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31053.